Skip to main content
Clinical Trials/NCT04356638
NCT04356638
Recruiting
Phase 3

A Partially Double-Blinded, Randomized, Controlled, Placebo-Controlled Study, a Phase III Trial of Safety and Efficacy of Premedication With Dexmedetomidine and Midazolam in Pediatric Patients

King Faisal Specialist Hospital & Research Center1 site in 1 country80 target enrollmentOctober 17, 2021

Overview

Phase
Phase 3
Intervention
Midazolam
Conditions
Anxiety State
Sponsor
King Faisal Specialist Hospital & Research Center
Enrollment
80
Locations
1
Primary Endpoint
Safety - Hemodynamic stability
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This research study to evaluate the relative efficacy of Dexmedetomidine, Midazolam, and compare them to the current KFSH&RC standard of care. Compare the safety and the frequency of adverse effects of treatment arms.

Registry
clinicaltrials.gov
Start Date
October 17, 2021
End Date
December 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ganesh Sivasankara

Consultant, Anesthesiology

King Faisal Specialist Hospital & Research Center

Eligibility Criteria

Inclusion Criteria

  • All pediatric outpatients coming for MRI investigations requiring general anesthesia at King Faisal Specialist Hospital \& Research Center (KFSH\&RC) age 1-12 years

Exclusion Criteria

  • Weight ≥ 40 kilograms
  • Allergies to the study drug
  • Refused to take the study drug
  • Severe learning disability
  • Patient on Digoxin medication
  • Patient on beta-blocker medication
  • Cardiac disease with abnormal conduction system
  • Nasal anatomical abnormality

Arms & Interventions

The sedative pre-medication oral Midazolam

Intervention: Midazolam

The sedative pre-medication intranasal Dexmedetomidine

Intervention: Dexmedetomidine

Placebo

Intervention: Placebo

Outcomes

Primary Outcomes

Safety - Hemodynamic stability

Time Frame: 30 Minutes

The systolic and diastolic blood pressures will be measured when the subject enters the recovery room, and then each ten minutes until the subject goes into the MRI suite and general anesthesia is induced.

Safety - Respiratory function

Time Frame: 30 Minutes

The respiratory rate will be measured when the subject enters the recovery room, and then each ten minutes until the subject goes into the MRI suite and general anesthesia is induced.

Anxiety Level

Time Frame: 30 Minutes

Comparison of the level of anxiety as measured by The Modified Yale Preoperative Anxiety Scale - Short Form (mYPAS-SF) at the time when the child checks in at the front desk (say mYPAS-SF1), with when the attempt will be made to insert an IV line (say mYPAS-SF2). This scale is a score ranging from four (little anxiety) to twenty two (much anxiety).

Oxygen saturation

Time Frame: 30 Minutes

The SpO2 will be measured when the subject enters the recovery room, and then each ten minutes until the subject goes into the MRI suite and general anesthesia is induced.

Secondary Outcomes

  • Visual Analog Scale for child anxiety(10 Minutes)
  • IV cannulation procedure completion and number of attempts - yes or no(10 Minutes)
  • Assessment of the Pediatric Anesthesia Emergence Delirium (PAED-scale) for the subjects(60 Minutes)
  • Post Hospitalization Behavior Questionnaire for Ambulatory Surgery(Day 2 post procedure)
  • Likert scale assessment of how cooperative/easy to handle the child(10 Minutes)

Study Sites (1)

Loading locations...

Similar Trials